No Data
No Data
Insider Sale: See Remarks of $EOLS (EOLS) Sells 2,252 Shares
Fewer Investors Than Expected Jumping On Evolus, Inc. (NASDAQ:EOLS)
Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Ultragenyx Pharmaceutical (RARE) and Henry Schein (HSIC)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
No Data